XML 28 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
(LOSS) INCOME PER SHARE ATTRIBUTABLE TO THE STOCKHOLDERS OF ARGAN, INC. (Tables)
9 Months Ended
Oct. 31, 2019
(LOSS) INCOME PER SHARE ATTRIBUTABLE TO THE STOCKHOLDERS OF ARGAN, INC.  
Schedule of computations of basic and diluted (loss) income per share

Basic and diluted (loss) income per share are computed as follows (shares in thousands except in note(1) below the charts):

 

 

 

 

 

 

 

 

 

 

Three Months Ended October 31, 

 

    

2019

    

2018

 

 

 

 

 

 

 

Net (loss) income attributable to the stockholders of Argan, Inc.

 

$

(6,855)

 

$

32,434

 

 

 

 

 

 

 

Weighted average number of shares outstanding - basic

 

 

15,633

 

 

15,569

Effects of stock awards (1)

 

 

 —

 

 

133

Weighted average number of shares outstanding - diluted

 

 

15,633

 

 

15,702

Net (loss) income per share attributable to the stockholders of Argan, Inc.

 

 

 

 

 

 

Basic

 

$

(0.44)

 

$

2.08

Diluted

 

$

(0.44)

 

$

2.07

 

 

 

 

 

 

 

 

 

 

Nine Months Ended October 31, 

 

    

2019

    

2018

 

 

 

 

 

 

 

Net (loss) income attributable to the stockholders of Argan, Inc.

 

$

(35,501)

 

$

54,243

 

 

 

 

 

 

 

Weighted average number of shares outstanding - basic

 

 

15,617

 

 

15,568

Effects of stock awards (1)

 

 

 —

 

 

117

Weighted average number of shares outstanding - diluted

 

 

15,617

 

 

15,685

Net (loss) income per share attributable to the stockholders of Argan, Inc.

 

 

 

 

 

 

Basic

 

$

(2.27)

 

$

3.48

Diluted

 

$

(2.27)

 

$

3.46


(1)

For the three and nine months ended October 31, 2019, the weighted average numbers of shares determined on a dilutive basis excludes the effects of outstanding stock awards. All common stock equivalents are considered to be antidilutive for these periods as the Company incurred net losses in each period. The weighted average numbers for the three and nine months ended October 31, 2018 exclude the effects of antidilutive stock options covering 581,500 shares for each period; the options had exercise prices per share in excess of the average market price per share for each period.